Amyloidosis, synucleinopathy, and prion encephalopathy in a neuropathic lysosomal storage disease: the CNS-biomarker potential of peripheral blood.

Amyloidosis, synucleinopathy, and prion encephalopathy in a neuropathic lysosomal storage disease: the CNS-biomarker potential of peripheral blood.
复制标题

DOI:
10.1371/journal.pone.0080142
复制
发表时间:
2013
期刊:
影响因子:
3.7
通讯作者:
Fu H
Fu H
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Naughton BJ;Duncan FJ;Murrey D;Ware T;Meadows A;McCarty DM;Fu H

文献摘要

参考文献

被引文献

相似文献

粘多糖症(MPS)IIIB是一种具有复杂病理基础的破坏性神经病理性溶酶体贮积性疾病。这项研究利用小鼠模型确定了外周血中可能与MPS IIIB发病相关的分子特征。在汇集的RNA上的全基因组基因表达微阵列显示MPS IIIB小鼠血液中2,802个转录本的失调,反映了MPS IIIB的病理复杂性,几乎涵盖了所有先前报道和尚未探索的疾病方面。重要的是,据报道,许多失调的基因是组织特有的。进一步分析与神经退行性变的主要途径相关的多个基因表明,MPS IIIB的淀粉样变性和突触核病之间存在很强的脑-血相关性。我们还在MPS IIIB小鼠的中枢神经系统中检测到了PrNP的沉积和血液中的PrNP异常,提示PRNP的聚集参与了神经病理。α-N-乙酰氨基葡萄糖苷酶在中枢神经系统和外周组织中的有效恢复和溶酶体储存病理的清除,以及脑和血液中受损的神经变性分子通路的纠正。我们的数据表明,血液中的分子变化可能反映中枢神经系统的病理状态,并为识别MPS、IIIB和可能的其他神经系统疾病的潜在中枢神经系统特异性生物标志物提供了有用的工具。
Mucopolysaccharidosis (MPS) IIIB is a devastating neuropathic lysosomal storage disease with complex pathology. This study identifies molecular signatures in peripheral blood that may be relevant to MPS IIIB pathogenesis using a mouse model. Genome-wide gene expression microarrays on pooled RNAs showed dysregulation of 2,802 transcripts in blood from MPS IIIB mice, reflecting pathological complexity of MPS IIIB, encompassing virtually all previously reported and as yet unexplored disease aspects. Importantly, many of the dysregulated genes are reported to be tissue-specific. Further analyses of multiple genes linked to major pathways of neurodegeneration demonstrated a strong brain-blood correlation in amyloidosis and synucleinopathy in MPS IIIB. We also detected prion protein (Prnp) deposition in the CNS and Prnp dysregulation in the blood in MPS IIIB mice, suggesting the involvement of Prnp aggregation in neuropathology. Systemic delivery of trans-BBB-neurotropic rAAV9-hNAGLU vector mediated not only efficient restoration of functional α-N-acetylglucosaminidase and clearance of lysosomal storage pathology in the central nervous system (CNS) and periphery, but also the correction of impaired neurodegenerative molecular pathways in the brain and blood. Our data suggest that molecular changes in blood may reflect pathological status in the CNS and provide a useful tool for identifying potential CNS-specific biomarkers for MPS IIIB and possibly other neurological diseases.
DOI: 10.1038/mt.2009.71
发表时间: 2009-07-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Duque, Sandra;Joussemet, Beatrice;Barkats, Martine
通讯作者: Barkats, Martine
DOI: 10.1097/wnr.0b013e32834d2216
发表时间: 2012-01-04
期刊: Neuroreport
影响因子: 1.7
作者:
Naughton BJ;Thirtamara-Rajamani K;Wang C;During MJ;Gu HH
通讯作者: Gu HH
DOI: 10.1038/nbt.1610
发表时间: 2010-03
影响因子: 46.9
作者:
通讯作者: --
DOI: 10.1097/00005072-199908000-00004
发表时间: 1999-08-01
影响因子: 3.2
作者:
Ginsberg, SD;Galvin, JE;Trojanowski, JQ
通讯作者: Trojanowski, JQ
DOI: 10.1016/j.cell.2012.02.040
发表时间: 2012-03-16
期刊: Cell
影响因子: 64.5
作者:
Huang Y;Mucke L
通讯作者: Mucke L